Literature DB >> 1347908

The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease.

J I Sage1, M H Mark.   

Abstract

Continuous dopaminergic stimulation has been shown to stabilize motor fluctuations in patients with advanced Parkinson's disease (PD) who do not respond to more conventional forms of therapy. Levodopa infusions confer immediate benefit as a direct result of maintaining steady plasma levodopa concentrations. Fluctuations of synaptic dopamine inherent in the usual oral treatment of PD might result in deleterious postsynaptic changes. Some of these presumed receptor alterations might revert as a consequence of continuous levodopa infusion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347908

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.

Authors:  M Yamamoto; M Yokochi; S Kuno; Y Hattori; Y Tsukamoto; H Narabayashi; H Tohgi; Y Mizuno; H Kowa; N Yanagisawa; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.

Authors:  A Colzi; K Turner; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

Review 3.  Diagnosis and treatment of Parkinson's disease in the elderly.

Authors:  J I Sage; M H Mark
Journal:  J Gen Intern Med       Date:  1994-10       Impact factor: 5.128

Review 4.  Novel oral drug formulations. Their potential in modulating adverse effects.

Authors:  A T Florence; P U Jani
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

5.  Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum.

Authors:  Kathy Steece-Collier; David J Rademacher; Katherine Soderstrom
Journal:  Basal Ganglia       Date:  2012-02-11

6.  Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor.

Authors:  C Weller; C J O'Neill; A Charlett; S G Bowes; A Purkiss; P W Nicholson; R J Dobbs; S M Dobbs
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

Review 7.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 8.  Concentration-effect relationship of levodopa in patients with Parkinson's disease.

Authors:  S Harder; H Baas; S Rietbrock
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

9.  Potential cellular and regenerative approaches for the treatment of Parkinson's disease.

Authors:  Emma L Lane; Olivia J Handley; Anne E Rosser; Stephen B Dunnett
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.